Clinical Trial

Route 92 Medical Files Patent Infringement Suit Against Q’Apel Medical

SAN MATEO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated…

3 months ago

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing…

3 months ago

Prenetics Announces Second Quarter 2024 Financial Results

Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New…

3 months ago

Mass General Hospital researcher Gary Ruvkun honored with 2024 Nobel Prize

Physiology or Medicine Prize award honors discovery of small regulatory RNAsBoston, MA, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Media notice:…

3 months ago

Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology

DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics…

3 months ago

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a clinical-stage company in late-stage development…

3 months ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated…

3 months ago

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of…

3 months ago

Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium

SAN DIEGO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today…

3 months ago

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

NOVATO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development…

3 months ago